Global Non-coding RNA Assays Market

Non-coding RNA Assays Comprehensive Study by Type (Infrastructural non coding RNA, Regulatory non coding RNA), End-User (Laboratories, Research Centers, Others), Size (Small, Medium, Large, Others) Players and Region - Global Market Outlook to 2030

Non-coding RNA Assays Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Non-coding RNA Assays Market Scope
An RNA molecule that is not translated into a protein is known as a non-coding RNA (ncRNA). An RNA gene is the DNA sequence from which a functional non-coding RNA is transcribed. Transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs), as well as short RNAs including microRNAs, siRNAs, piRNAs, snoRNAs, snRNAs, exRNAs, scaRNAs, and long ncRNAs like Xist and HOTAIR, are abundant and functionally significant. The amount of non-coding DNA found in different species varies substantially. Only a small percentage of the genome is responsible for coding proteins, but a growing percentage of the genome is being discovered to have regulatory activities. As predicted in the 1960s, when there is a lot of non-coding DNA, a lot of it appears to have no biological role. Since then, this non-functional section has been dubbed "junk DNA" in a contentious manner.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia Pacific
Largest MarketNorth America
UnitValue (USD Million)
Key Companies ProfiledSpringer Nature Limited (United Kingdom), Applied Microarrays Inc. (United States), C D Genomics (United States), RELX Group (United Kingdom), MilliporeSigma (United States), QIAGEN (Germany), Agilent Technologies, Inc. (United States) and Danaher Corporation (United States)
CAGR%


The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Non-coding RNA Assays market throughout the predicted period.

Springer Nature Limited (United Kingdom), Applied Microarrays Inc. (United States), C D Genomics (United States), RELX Group (United Kingdom), MilliporeSigma (United States), QIAGEN (Germany), Agilent Technologies, Inc. (United States) and Danaher Corporation (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Eppendorf SE (Germany) and Thermo Fisher Scientific Company (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Non-coding RNA Assays market by Type and Region with country level break-up.

On the basis of geography, the market of Non-coding RNA Assays has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement.




Influencing Trend:
Innovation of New Techniques

Market Growth Drivers:
Rising Government Initiatives to Promote Life Science Research Projects

Challenges:
Lack of Researchers in Developing Countries

Restraints:
High Cost of Non-Coding RNA Assay

Opportunities:
Rising Focus on Biomarker Discovery

Key Target Audience
Venture Capitalists and Private Equity Firms, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Type
  • Infrastructural non coding RNA
  • Regulatory non coding RNA
By End-User
  • Laboratories
  • Research Centers
  • Others

By Size
  • Small
  • Medium
  • Large
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Government Initiatives to Promote Life Science Research Projects
    • 3.3. Market Challenges
      • 3.3.1. Lack of Researchers in Developing Countries
    • 3.4. Market Trends
      • 3.4.1. Innovation of New Techniques
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Non-coding RNA Assays, by Type, End-User, Size and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Non-coding RNA Assays (Value)
      • 5.2.1. Global Non-coding RNA Assays by: Type (Value)
        • 5.2.1.1. Infrastructural non coding RNA
        • 5.2.1.2. Regulatory non coding RNA
      • 5.2.2. Global Non-coding RNA Assays by: End-User (Value)
        • 5.2.2.1. Laboratories
        • 5.2.2.2. Research Centers
        • 5.2.2.3. Others
      • 5.2.3. Global Non-coding RNA Assays Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Non-coding RNA Assays: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Springer Nature Limited (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Applied Microarrays Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. C D Genomics (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. RELX Group (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. MilliporeSigma (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. QIAGEN (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Agilent Technologies, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Danaher Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Non-coding RNA Assays Sale, by Type, End-User, Size and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Non-coding RNA Assays (Value)
      • 7.2.1. Global Non-coding RNA Assays by: Type (Value)
        • 7.2.1.1. Infrastructural non coding RNA
        • 7.2.1.2. Regulatory non coding RNA
      • 7.2.2. Global Non-coding RNA Assays by: End-User (Value)
        • 7.2.2.1. Laboratories
        • 7.2.2.2. Research Centers
        • 7.2.2.3. Others
      • 7.2.3. Global Non-coding RNA Assays Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Non-coding RNA Assays: by Type(USD Million)
  • Table 2. Non-coding RNA Assays Infrastructural non coding RNA , by Region USD Million (2018-2023)
  • Table 3. Non-coding RNA Assays Regulatory non coding RNA , by Region USD Million (2018-2023)
  • Table 4. Non-coding RNA Assays: by End-User(USD Million)
  • Table 5. Non-coding RNA Assays Laboratories , by Region USD Million (2018-2023)
  • Table 6. Non-coding RNA Assays Research Centers , by Region USD Million (2018-2023)
  • Table 7. Non-coding RNA Assays Others , by Region USD Million (2018-2023)
  • Table 8. South America Non-coding RNA Assays, by Country USD Million (2018-2023)
  • Table 9. South America Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 10. South America Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 11. South America Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 12. Brazil Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 13. Brazil Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 14. Brazil Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 15. Argentina Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 16. Argentina Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 17. Argentina Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 18. Rest of South America Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 19. Rest of South America Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 20. Rest of South America Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 21. Asia Pacific Non-coding RNA Assays, by Country USD Million (2018-2023)
  • Table 22. Asia Pacific Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 23. Asia Pacific Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 24. Asia Pacific Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 25. China Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 26. China Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 27. China Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 28. Japan Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 29. Japan Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 30. Japan Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 31. India Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 32. India Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 33. India Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 34. South Korea Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 35. South Korea Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 36. South Korea Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 37. Taiwan Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 38. Taiwan Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 39. Taiwan Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 40. Australia Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 41. Australia Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 42. Australia Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 43. Rest of Asia-Pacific Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 44. Rest of Asia-Pacific Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 45. Rest of Asia-Pacific Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 46. Europe Non-coding RNA Assays, by Country USD Million (2018-2023)
  • Table 47. Europe Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 48. Europe Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 49. Europe Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 50. Germany Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 51. Germany Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 52. Germany Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 53. France Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 54. France Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 55. France Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 56. Italy Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 57. Italy Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 58. Italy Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 59. United Kingdom Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 60. United Kingdom Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 61. United Kingdom Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 62. Netherlands Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 63. Netherlands Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 64. Netherlands Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 65. Rest of Europe Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 66. Rest of Europe Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 67. Rest of Europe Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 68. MEA Non-coding RNA Assays, by Country USD Million (2018-2023)
  • Table 69. MEA Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 70. MEA Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 71. MEA Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 72. Middle East Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 73. Middle East Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 74. Middle East Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 75. Africa Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 76. Africa Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 77. Africa Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 78. North America Non-coding RNA Assays, by Country USD Million (2018-2023)
  • Table 79. North America Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 80. North America Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 81. North America Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 82. United States Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 83. United States Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 84. United States Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 85. Canada Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 86. Canada Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 87. Canada Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 88. Mexico Non-coding RNA Assays, by Type USD Million (2018-2023)
  • Table 89. Mexico Non-coding RNA Assays, by End-User USD Million (2018-2023)
  • Table 90. Mexico Non-coding RNA Assays, by Size USD Million (2018-2023)
  • Table 91. Company Basic Information, Sales Area and Its Competitors
  • Table 92. Company Basic Information, Sales Area and Its Competitors
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Non-coding RNA Assays: by Type(USD Million)
  • Table 100. Non-coding RNA Assays Infrastructural non coding RNA , by Region USD Million (2025-2030)
  • Table 101. Non-coding RNA Assays Regulatory non coding RNA , by Region USD Million (2025-2030)
  • Table 102. Non-coding RNA Assays: by End-User(USD Million)
  • Table 103. Non-coding RNA Assays Laboratories , by Region USD Million (2025-2030)
  • Table 104. Non-coding RNA Assays Research Centers , by Region USD Million (2025-2030)
  • Table 105. Non-coding RNA Assays Others , by Region USD Million (2025-2030)
  • Table 106. South America Non-coding RNA Assays, by Country USD Million (2025-2030)
  • Table 107. South America Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 108. South America Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 109. South America Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 110. Brazil Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 111. Brazil Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 112. Brazil Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 113. Argentina Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 114. Argentina Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 115. Argentina Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 116. Rest of South America Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 117. Rest of South America Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 118. Rest of South America Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 119. Asia Pacific Non-coding RNA Assays, by Country USD Million (2025-2030)
  • Table 120. Asia Pacific Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 121. Asia Pacific Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 122. Asia Pacific Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 123. China Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 124. China Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 125. China Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 126. Japan Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 127. Japan Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 128. Japan Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 129. India Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 130. India Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 131. India Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 132. South Korea Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 133. South Korea Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 134. South Korea Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 135. Taiwan Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 136. Taiwan Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 137. Taiwan Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 138. Australia Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 139. Australia Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 140. Australia Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 141. Rest of Asia-Pacific Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 142. Rest of Asia-Pacific Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 143. Rest of Asia-Pacific Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 144. Europe Non-coding RNA Assays, by Country USD Million (2025-2030)
  • Table 145. Europe Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 146. Europe Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 147. Europe Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 148. Germany Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 149. Germany Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 150. Germany Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 151. France Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 152. France Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 153. France Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 154. Italy Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 155. Italy Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 156. Italy Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 157. United Kingdom Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 158. United Kingdom Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 159. United Kingdom Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 160. Netherlands Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 161. Netherlands Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 162. Netherlands Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 163. Rest of Europe Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 164. Rest of Europe Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 165. Rest of Europe Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 166. MEA Non-coding RNA Assays, by Country USD Million (2025-2030)
  • Table 167. MEA Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 168. MEA Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 169. MEA Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 170. Middle East Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 171. Middle East Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 172. Middle East Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 173. Africa Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 174. Africa Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 175. Africa Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 176. North America Non-coding RNA Assays, by Country USD Million (2025-2030)
  • Table 177. North America Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 178. North America Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 179. North America Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 180. United States Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 181. United States Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 182. United States Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 183. Canada Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 184. Canada Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 185. Canada Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 186. Mexico Non-coding RNA Assays, by Type USD Million (2025-2030)
  • Table 187. Mexico Non-coding RNA Assays, by End-User USD Million (2025-2030)
  • Table 188. Mexico Non-coding RNA Assays, by Size USD Million (2025-2030)
  • Table 189. Research Programs/Design for This Report
  • Table 190. Key Data Information from Secondary Sources
  • Table 191. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Non-coding RNA Assays: by Type USD Million (2018-2023)
  • Figure 5. Global Non-coding RNA Assays: by End-User USD Million (2018-2023)
  • Figure 6. South America Non-coding RNA Assays Share (%), by Country
  • Figure 7. Asia Pacific Non-coding RNA Assays Share (%), by Country
  • Figure 8. Europe Non-coding RNA Assays Share (%), by Country
  • Figure 9. MEA Non-coding RNA Assays Share (%), by Country
  • Figure 10. North America Non-coding RNA Assays Share (%), by Country
  • Figure 11. Global Non-coding RNA Assays share by Players 2023 (%)
  • Figure 12. Global Non-coding RNA Assays share by Players (Top 3) 2023(%)
  • Figure 13. Global Non-coding RNA Assays share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Springer Nature Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 16. Springer Nature Limited (United Kingdom) Revenue: by Geography 2023
  • Figure 17. Applied Microarrays Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Applied Microarrays Inc. (United States) Revenue: by Geography 2023
  • Figure 19. C D Genomics (United States) Revenue, Net Income and Gross profit
  • Figure 20. C D Genomics (United States) Revenue: by Geography 2023
  • Figure 21. RELX Group (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. RELX Group (United Kingdom) Revenue: by Geography 2023
  • Figure 23. MilliporeSigma (United States) Revenue, Net Income and Gross profit
  • Figure 24. MilliporeSigma (United States) Revenue: by Geography 2023
  • Figure 25. QIAGEN (Germany) Revenue, Net Income and Gross profit
  • Figure 26. QIAGEN (Germany) Revenue: by Geography 2023
  • Figure 27. Agilent Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Agilent Technologies, Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. Danaher Corporation (United States) Revenue: by Geography 2023
  • Figure 31. Global Non-coding RNA Assays: by Type USD Million (2025-2030)
  • Figure 32. Global Non-coding RNA Assays: by End-User USD Million (2025-2030)
  • Figure 33. South America Non-coding RNA Assays Share (%), by Country
  • Figure 34. Asia Pacific Non-coding RNA Assays Share (%), by Country
  • Figure 35. Europe Non-coding RNA Assays Share (%), by Country
  • Figure 36. MEA Non-coding RNA Assays Share (%), by Country
  • Figure 37. North America Non-coding RNA Assays Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Springer Nature Limited (United Kingdom)
  • Applied Microarrays Inc. (United States)
  • C D Genomics (United States)
  • RELX Group (United Kingdom)
  • MilliporeSigma (United States)
  • QIAGEN (Germany)
  • Agilent Technologies, Inc. (United States)
  • Danaher Corporation (United States)
Additional players considered in the study are as follows:
Eppendorf SE (Germany) , Thermo Fisher Scientific Company (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 195 Pages 78 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Non-coding RNA Assays Market Quantitative research analysis
Global Non-coding RNA Assays Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Non-coding RNA Assays Market are by type [Infrastructural non coding RNA and Regulatory non coding RNA], by end use application [].
The Non-coding RNA Assays Market is gaining popularity and expected to see strong valuation by 2030.
  • Rising Government Initiatives to Promote Life Science Research Projects

Know More About Global Non-coding RNA Assays Market Report?

Have a Query? Click Here

Other Related Reports

Radioembolization Therapy Comprehensive Study by Application (Hepatocellular Carcinoma, Liver Cancer), Procedure (Transarterial Radioembolization, Selective Internal Radiation Therapy), End User (Hos...
$ 3350
Kid Gym- Comprehensive Study by Type (Comprehensive Kid Gym, Special Kid Gym), Application (Private, Commercial) Players and Region - Global Market Outlook to 2030
$ 3500
Til Therapy- Comprehensive Study by Type (Single Injection, Multiple Injections), Application (Stomach Cancer, Cancer of Pancreas, Hepatoma, Uterine/Endometrial Carcinoma, Cervical Carcinoma, Urethra...
$ 3350
Clinical Trials Support Service- Comprehensive Study by End-users (Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies, Others), Indication (Inflammation, Oncology, Diabetes, Cardi...
$ 3650
Operating Theater (OT) Systems Comprehensive Study by Type (Modular Operation Theater, Orthopaedic Operation Theater, General Surgery Operation Theater, Head & Neck Operation Theater, Endoscopy Opera...
$ 3750
Psychiatric Software System- Comprehensive Study by Type (Electronic Health Records, Clinical Decision Support, Health Management, E-Prescribing, Tele-Health, Others), Function (Clinical, Administrat...
$ 3450